Form 4: PBSV Director Perlysky Acquires 20,000 Stock Options

Pharma-Bio Serv Director Dov Perlysky acquired 20,000 stock options with an exercise price of $0.54, vesting in two equal installments.

Summary

• Dov Perlysky, a Director and 10% Owner of Pharma-Bio Serv, Inc. (PBSV), reported the acquisition of 20,000 derivative securities.
• The acquired securities are stock options with an exercise price of $0.54 per share.
• The transaction date for this acquisition was January 10, 2026.
• These options will vest in two equal installments on July 10, 2026, and July 10, 2027.
• The expiration date for these stock options is January 10, 2031.
• Following this transaction, Dov Perlysky beneficially owns 20,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The acquisition of stock options by a director is generally viewed as a neutral to slightly positive event, as it aligns the director's financial interests with the long-term performance of the company's stock. It is a standard compensation practice.

Positives

• The acquisition of stock options by a director can signal alignment of interests between management and shareholders, as the director's compensation becomes tied to the company's stock performance.
• The grant of options is a common form of incentive compensation, potentially motivating the director to contribute to the company's long-term success.

Future Outlook

The stock options are scheduled to vest in two equal installments on July 10, 2026, and July 10, 2027, indicating future periods when the director will gain full ownership rights to the options.

Industry Context

This Form 4 filing reports an insider transaction, which is a routine disclosure for publicly traded companies. It reflects a specific compensation event for a director rather than a broader industry trend or competitive development.

Related Party Transactions

• The grant of 20,000 stock options to Dov Perlysky, a Director and 10% Owner, constitutes a transaction with a related party as part of his compensation.

Stakeholder Impact

• Shareholders: Potential for increased alignment of interests between the director and shareholders, as the director's compensation is tied to stock performance.
• Employees: No direct impact on general employees mentioned in this filing.

Next Steps

• First vesting of 10,000 stock options on July 10, 2026.
• Second vesting of 10,000 stock options on July 10, 2027.

Key Dates

Keywords

Pharma-Bio Serv, PBSV, Dov Perlysky, Stock Options, Insider Transaction, Director Compensation, SEC Form 4, Equity Grant, Vesting Schedule